RGC
NBIX icon

Roberts, Glore & Co’s Neurocrine Biosciences NBIX Stock Holding History

Roberts, Glore & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
+1,317
New +$195K 0.05% 228
2026
Q1 		– Sell
-1,492
Closed -$212K – 231
2025
Q4 		$212K Hold
1,492
– – 0.06% 211
2025
Q3 		$209K Buy
+1,492
New +$202K 0.06% 210
2025
Q1 		– Sell
-1,492
Closed -$204K – 209
2024
Q4 		$204K Buy
+1,492
New +$185K 0.06% 203
2024
Q3 		– Sell
-1,492
Closed -$205K – 212
2024
Q2 		$205K Hold
1,492
– – 0.06% 197
2024
Q1 		$206K Buy
+1,492
New +$204K 0.06% 201

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Roberts, Glore & Co's NBIX Position: Q2 2026 in Review

Roberts, Glore & Co opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,317 shares worth $222K. The stake represents 0.05% of the portfolio and ranks #228 among its holdings. This is a return to the name: Roberts, Glore & Co previously reported a position in NBIX as recently as Q4 2025.

Roberts, Glore & Co first reported a position in NBIX in Q1 2024 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Roberts, Glore & Co held 1,317 shares of Neurocrine Biosciences worth $222K as of Q2 2026.
  • Neurocrine Biosciences was a new Roberts, Glore & Co position in Q2 2026.
  • Neurocrine Biosciences made up 0.05% of Roberts, Glore & Co's portfolio in Q2 2026, its #228 holding.
  • Roberts, Glore & Co first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 6 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.